(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number
WO 01/40180 A2

(51) International Patent Classification[7]: C07D 207/16, A61K 31/401

(21) International Application Number: PCT/GB00/04572

(22) International Filing Date:
30 November 2000 (30.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9928330.1 30 November 1999 (30.11.1999) GB

(71) Applicant *(for all designated States except US)*: FERRING BV [NL/NL]; Polaris Avenue 144, NL-2132 JX Hoofddorp (NL).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: EVANS, David, Michael [GB/GB]; 114 Adelaide Road, St. Denys, Southampton SO17 2HX (GB).

(74) Agent: GEERING, Keith, Edwin; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL ANTIDIABETIC AGENTS



(57) Abstract: Compounds which are 1-(2'-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2, 3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R^3CO, groups $R^4COOC(R^5)(R^6)OCO$, methoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl; R^1 is selected from H, C_1-C_6 alkyl residues, $(CH_2)_aNHW^1$, $(CH_2)_bCOW^2$, $(CH_2)_cOW^3$, $CH(Me)OW^4$, $(CH_2)_d$-C_6H_4-W^5 and $(CH_2)_eSW^6$, where a is 2-5, b is 1-4, c is 1-2, d is 1-2, e is 1-3, W^1 is COW^6, CO_2W^6 or SO_2W^6, W^2 is OH, NH_2, OW^6 or NHW^6, W^3 is H or W^6, W^4 is H or W^6, W^5 is H, OH or OMe, and W^6 is C_1-C_6 alkyl, optionally substituted phenyl, optionally substituted heteroaryl or benzyl and R^2 is selected from H and $(CH_2)_n$-C_5H_3N-Y, where n is 2-4 and Y is H, F, Cl, NO_2 or CN, or R^1 and R^2 together are $-(CH_2)_p-$ where p is 3 or 4; R^3 is selected from H, C_1-C_6 alkyl and phenyl; R^4 is selected from H, C_1-C_6 alkyl, benzyl and optionally substituted phenyl; R^5 and R^6 are each independently selected from H and C_1-C_6 alkyl or together are $-(CH_2)_m-$, where m is 4-6; R^7 is selected from pyridyl and optionally substituted phenyl; R^8 is selected from H and C_1-C_3 alkyl; and R^9 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy and phenyl.

WO 01/40180 A2